Novartis Shanghai R&D Center To Focus On Diseases Prevalent In China
This article was originally published in PharmAsia News
Executive Summary
Novartis will break ground in July 2007 on an integrated biomedical R&D center in Shanghai's Zhangjiang Hi-Tech park as part of a commitment to conduct research in China, the Swiss company announced Nov. 6. Novartis will initially invest $96 mil. to create the Shanghai site
You may also be interested in...
Novartis Lines Up $1 Billion For China R&D
Novartis announced Nov. 3 a five-year, $1 billion investment in China, upping the ante for multinationals trying to build strong foundations in China's burgeoning R&D space
Novartis Lines Up $1 Billion For China R&D
Novartis announced Nov. 3 a five-year, $1 billion investment in China, upping the ante for multinationals trying to build strong foundations in China's burgeoning R&D space
Novartis Lines Up $1 Billion For China R&D
In-country research staff will increase over six-fold to approximately 1,000.